Synairgen PLC (AIM:SNG, OTC:SYGGF) said America’s National Institute of Allergy and Infectious Diseases has halted a phase II/III COVID-19 trial that included the UK group’s lead asset, SNG001.
It said the development was due to the “significant shift in the nature of the pandemic which would necessitate a substantial modification of the study design not feasible in this multiple treatment-arm, platform trial”.
It added that the lead investigators from the ACTIV-2 study and Synairgen are in “ongoing discussions to try to identify an appropriate clinical trial to continue the evaluation of SNG001”.
Synairgen chief executive Richard Marsden added that his team was “actively seeking inclusion” in platform trials for hospitalised patients and is working closely with America’s National Institutes for Health to find a “suitable trial” for SNG001 in home-based patients.
He told investors: "Conducting clinical trials in the time of COVID-19 is challenging but as important now as at the start of the pandemic.
“Even with improved standard of care, there remains a critical need to prevent progression to severe disease and death.”